Skip to search formSkip to main contentSkip to account menu

Eylea

National Institutes of Health

Related topics

Related topics

3 relations
0.05 ML aflibercept 40 MG/ML Injection [Eylea]aflibercept Injection [Eylea]

Broader (1)

aflibercept

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
THE EFFECT OF AGE ON AFLIBERCEPT (EYLEA) RESPONSE IN DIABETIC MACULAR EDEMA.
PURPOSE To investigate the effect of age on aflibercept (Eylea) response in macular edema secondary to treatment-naive diabetic… 
Review
2019
Review
2019
Long‐acting intraocular Delivery strategies for biological therapy of age‐related macular degeneration
2019
2019
Sustained Anti-Vascular Endothelial Growth Factor Activity of Aflibercept (Eylea) After Storage in Polycarbonate Syringes Used for Intravitreal Injection: A Pathway to Safety and Efficiency.
Purpose: Aflibercept (Eylea™, Regeneron) is supplied in single-use glass vials along with 1 cc polycarbonate syringes. We sought… 
2019
2019
Eylea (Aflibercept) Injection Approved for Diabetic Retinopathy
Originally approved in 2011, aflibercept is a vascular endothelial growth factor (VEGF) inhibitor. 
2019
2019
Ultrastruktureller und klinischer Vergleich des Ergebnisses bei PDR-Patienten, behandelt mit Ranibizumab oder Aflibercept – von Grundlagenforschungen zu den klinischen Therapien
Zusammenfassung Hintergrund Die proliferative diabetische Retinopathie (PDR) ist eine der häufigsten Erblindungsursachen weltweit… 
2018
2018
Effect of intravitreal aflibercept (Eylea®) on retrobulbar hemodynamics in patients with neovascular age-related macular degeneration
PurposeTo investigate the short-term effect of single intravitreal aflibercept injection on retrobulbar blood flow in patients… 
2018
2018
Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro
Aim: Treatment of exudative age-related macular degeneration by using vascular endothelial growth factor (VEGF) antagonists is… 
2016
2016
Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report
Background: We present an interesting case of bilateral retinitis pigmentosa (RP)-associated cystoid macular oedema that… 
Review
2014
Review
2014
Intravitreal Aflibercept (Eylea®): A Review of Its Use in Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion
Aflibercept is a fully human, recombinant fusion protein that acts as a soluble decoy receptor for vascular endothelial growth… 
2014
2014
Ocular distribution and pharmacokinetics of 125I‐OPT302 and 125I‐Aflibercept (EYLEA) following intravitreal administration to pigmented rabbits
Purpose OPT‐302 is a soluble receptor that specifically and potently blocks VEGF‐C and VEGF‐D activity which are involved in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)